Report library

Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)

This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals, a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

August 2, 2022

Social Media in Pharma

$2,995.00

While social media is still relatively new, it has been heralded as one of the most significant changes in the way that people communicate with one another. Despite this, the pharmaceutical industry has been slow to become involved with social media, fearing compliance and regulatory breaches and preferring to stay with the more traditional routes of communication, such as representative visits and emails. However, the growing popularity of social media, combined with a number of positive examples from both within and outside the pharmaceutical industry, has led to an increasing number of pharmaceutical companies looking to grow their social media presence and build on the unique opportunities these platforms offer.

January 27, 2017

Tyvaso for Pulmonary Arterial Hypertension

$89.00

The literature search was undertaken via multiple search engines and strategies with review of cited and associated articles to provide a comprehensive discussion on the topic. Expert opinion: While safe and well tolerated, inhaled treprostinil sodium should be limited, based on available data, to use as add-on therapy for patients with Group I pulmonary hypertension not effectively controlled on oral therapy.

November 29, 2016

CMOs in China and India: Still the Places to be?

$5,000.00

Low-cost and skilled workforces in China and India have positioned both countries as increasingly important manufacturing hubs for pharmaceutical companies, as they seek to contain costs while retaining quality outsourcing partners.

Despite the apparent inevitability of the contract manufacturing organization (CMO) sector’s growth in China and India, a recent wave of scandals has put significant dents in the reputations of both countries as locations for foreign firms to manufacture drugs. Rising costs have also caused some firms to question whether using one of the region’s many CMOs is worth the risk.

November 3, 2016

UK Healthcare System Overview

$2,995.00

Reform of the NHS is underway despite widespread controversy and opposition from physicians, and will necessitate a change in the way pharmaceutical companies work with key stakeholders.

November 2, 2016

Big Pharma Outlook 2015

Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies’ sharpened focus on high-performing markets.

September 28, 2016

Orphan Drug Market Outlook to 2017

Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition.

September 28, 2016

Q2 2016 Earnings Previews

Datamonitor Healthcare previews Q2 2016 earnings for companies in the PharmaVitae portfolio. Companies will be continuously added the day before presentations.

September 28, 2016

Rheumatoid Arthritis Payer Interview – UK

$599.00

A UK payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

August 22, 2019

Big Pharma Licensing Trends, 2014–18

$2,995.00

An analysis of the drug-focused licensing deals (out-licensing and in-licensing) made by Big Pharma companies shows an uptick in partnering from 2014 to 2015, followed by a slight decrease in 2016 that has held steady through 2018. Despite that slight decline, the peer set increased deal volume by roughly 15% between the beginning and the end of the five-year period. Total deal values rose even more, roughly 25%.

August 20, 2019

Vaccines Market Access in Emerging Markets

Emerging markets account for approximately 18% of the global vaccines market, which is valued at more than $24bn. However, there are indications that this is an underestimate, and some observers forecast that the overall marketplace will reach $50bn by the mid2020s.

August 29, 2019

Market Spotlight: Idiopathic pulmonary fibrosis (IPF)

This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis (IPF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

September 29, 2022

Market Spotlight: Acute Decompensated Heart Failure (ADHF)

Approved drugs in the ADHF – preserved ejection fraction (acute HFpEF) space target natriuretic peptide receptors. These drugs are administered via the intravenous route.

September 8, 2022

Market Spotlight: Migraine

This Market Spotlight report covers the migraine market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

August 17, 2020